Form 8-K - Current report:
SEC Accession No. 0000950170-25-026063
Filing Date
2025-02-25
Accepted
2025-02-25 07:05:09
Documents
13
Period of Report
2025-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fulc-20250225.htm   iXBRL 8-K 42281
2 EX-99.1 fulc-ex99_1.htm EX-99.1 128748
3 GRAPHIC img189780767_0.jpg GRAPHIC 54462
  Complete submission text file 0000950170-25-026063.txt   370715

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20250225.xsd EX-101.SCH 25038
15 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20250225_htm.xml XML 4747
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 25659341
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)